Geert Frederix

Associate Professor

Strategic program(s):

Contact

gfreder2@umcutrecht.nl

Pure profile

Recent publications

All publications

Expected costs and benefits of genetic counselling and germline genetic testing in metastatic prostate cancer Michiel Vlaming, Lambertus A L M Kiemeney, Wouter Koole, Inge M van Oort, Eveline M A Bleiker, Margreet G E M Ausems, Geert W J Frederix
Human Genetics, 2026, vol. 145

Surgical Quality Assessment of paravertebral catheter placement in minimally invasive esophagectomy D. C. van der Aa, M. D. Teeken, C. D. Kooij, J. Hermanides, M. L. Feenstra, S. S. Gisbertz, J. P. Ruurda, M. W. Hollmann, E. Cheong, M. Marsman, M. I. van Berge Henegouwen, R. van Hillegersberg, W. J. Eshuis, E. M. de Groot, B. F. Kingma, F. Daams, O. F.C. van den Bosch, W. ten Hoope, L. Goense, M. D.P. Luyer, G. A.P. Nieuwenhuijzen, H. J. Scholten, M. Buise, M. J. van Det, G. W.J. Frederix, E. A. Kouwenhoven, A. F. van der Meer,
European Journal of Surgical Oncology, 2026, vol. 52

Cost-effectiveness of pre-emptive pharmacogenetic testing Taichi Ochi, Manon G den Uil, Greta Piazza, Geert W J Frederix, Eelko Hak, Vera H M Deneer, Talitha L Feenstra
PLoS ONE, 2026, vol. 21

Choice and impact of EQ-5D-5L value set in cost-utility analyses alongside multinational trials Aniek E M Schouten, Geert W J Frederix, Martijn M Stuiver, Felix Fischer, Anouk E Hiensch, Krister Cromm, Bernard Canaud, Giovanni F M Strippoli, Anne M May, Miriam P van der Meulen,
PLoS ONE, 2026, vol. 21

Adoption of Managed Entry Agreements for Advanced Therapy Medicinal Products Andrea Greco, Geert W J Frederix, Lotty Hooft, Renske M T Ten Ham
Value in Health, 2026, vol. 29, p.1608-1617

Cost implications of early treatment discontinuation in cancer H. Colinda Post, Kirsten Opmeer, Tim Schutte, Marijke H. Delsing, Lonneke Timmers, Carla E.M. Hollak, Hanneke W.M. Van Laarhoven, Geert W.J. Frederix
Oncologist, 2026, vol. 31